NextCell Pharma AB

OM:NXTCL Stock Report

Market Cap: SEK 184.2m

NextCell Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Mathias Svahn

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.7%
Management average tenure2.5yrs
Board average tenureno data

Recent management updates

Recent updates

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Mar 09
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

Oct 07
We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

May 23
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Feb 01
NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Sep 21
We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31
Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15
We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Mathias Svahn's remuneration changed compared to NextCell Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-SEK 42m

May 31 2024n/an/a

-SEK 37m

Feb 29 2024n/an/a

-SEK 39m

Nov 30 2023n/an/a

-SEK 41m

Aug 31 2023n/an/a

-SEK 40m

May 31 2023n/an/a

-SEK 40m

Feb 28 2023n/an/a

-SEK 38m

Nov 30 2022n/an/a

-SEK 37m

Aug 31 2022n/an/a

-SEK 35m

May 31 2022n/an/a

-SEK 30m

Feb 28 2022n/an/a

-SEK 28m

Nov 30 2021n/an/a

-SEK 26m

Aug 31 2021n/an/a

-SEK 25m

May 31 2021n/an/a

-SEK 25m

Feb 28 2021n/an/a

-SEK 23m

Nov 30 2020n/an/a

-SEK 19m

Aug 31 2020n/an/a

-SEK 18m

May 31 2020n/an/a

-SEK 17m

Feb 29 2020n/an/a

-SEK 17m

Nov 30 2019n/an/a

-SEK 16m

Aug 31 2019SEK 984kSEK 984k

-SEK 18m

May 31 2019n/an/a

-SEK 17m

Feb 28 2019n/an/a

-SEK 15m

Nov 30 2018n/an/a

-SEK 16m

Compensation vs Market: Insufficient data to establish whether Mathias's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Mathias's compensation with company performance.

CEO

Mathias Svahn (48 yo)

no data

Tenure

SEK 983,528

Compensation

Dr. Mathias Svahn, Ph D is Founder of NextCell Pharma AB(also known as Cellaviva AB) and serves as its Chief Executive Officer. Dr. Svahn was an Executive Director at NextCell Pharma AB.

Leadership Team

NamePositionTenureCompensationOwnership
Mathias Svahn
Founder & CEOno dataSEK 983.53k0.69%
SEK 1.3m
Patrik Fagerholm
Chief Financial Officer3.3yrsno datano data
Lindsay Davies
Chief Scientific Officer4.6yrsno datano data
Edvard Smith
Chief Medical Officer & Directorno datano datano data
Sofie Jansson
CEO of Cellaviva1.8yrsno datano data
Sofia Sisay
Head of Clinical Trials1.8yrsno datano data

2.5yrs

Average Tenure

46.5yo

Average Age

Experienced Management: NXTCL's management team is considered experienced (2.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 19:36
End of Day Share Price 2025/01/08 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NextCell Pharma AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution